Drug Updates

Drug updates provide the latest information and relevant warnings and notifications.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Update on Drugs and Drug News: November-December 2014

Update on Omalizumab (Xolair®), Pembrolizumab (Keytruda®), Oritavancin (Orbactiv™), and Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®)

Update on Drugs and Drug News: September-October 2014

Update on Tedizolid phosphate tablets and IV injection (Sivextro™), Hyaluronic acidbased dermal filler (Restylane® Silk), Trifarotene, Icatibant SC injection (Firazyr®), C1 esterase inhibitor (Ruconest®), Methotrexate SC injection (Rasuvo™), Tavaborole 5% topical solution (Kerydin™), Nivolumab IV infusion (Opdivo®), Doxycycline hyclate tablets (Acticlate™)

Update on Drugs and Drug News: July-August 2014

Update on drugs Metronidazole 1.3% vaginal gel (Actavis plc), Ecallantide for SC injection (Kalbitor®), Dalbavancin for IV injection (Dalvance™), Taliglucerase alfa for IV injection (Elelyso™), and Efinaconazole 10% topical solution (Jublia®)

Update on Drugs and Drug News: May-June 2014

Update on Brimonidine tartrate 0.33% topical gel (Onreltea®Mirvaso®), Apremilast tablets (Otezla®), Miltefosine capsules (Impavido®), Hydrogel wound dressing (Loutrex®), Omalizumab for SC injection (Xolair®), Propranolol hydrochloride oral solution (Hemangeol™), Microbicide-coated condom Vivagel® (SPL7013 gel)

Update on Drugs and Drug News: March-April 2014

Update on Trametinib + Dabrafenib (Mekinist® + Tafinlar®), Tretinoin gel microsphere 0.08% (Retin-A Micro®), Fluocinonide cream 0.1%, Hydrogel wound dressing (Loutrex®), Scar treatment (Microcyn®)

Update on Drugs and Drug News: January-February 2014

Update on Hyaluronic acid gel dermal filler (Juvéderm Voluma™XC), Methotrexate injection (Otrexup™), Luliconazole 1% cream (Luzu®), Smallpox vaccine (Imvamune®)

Update on Drugs and Drug News: November-December 2013

Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)

Update on Drugs and Drug News: September-October 2013

Update on Dabrafenib mesilate capsule (Tafinlar™), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)

Update on Drugs and Drug News: July-August 2013

Update on Dabrafenib mesilate capsule (Tafinlar®), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)

Update on Drugs and Drug News: May-June 2013

Update on Acyclovir 50 mg buccal tablets (Sitavig®), Acyclovir 5% + hydrocortisone 1% cream (Xerese®), Botulinum toxin type A for injection (Dysport®), Desoximetasone 0.25% topical spray (Topicort®), Carbinoxamine maleate extendedrelease oral suspension (Karbinal™ ER), and C1-esterase inhibitor (Berinert®)

Update on Drugs and Drug News: March-April 2013

Update on Ingenol mebutate gel (0.015%, 0.05%) Picato™, Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), and Hydrogel for skin and wound care (Vashe® Skin and Wound Hydrogel)

Update on Drugs and Drug News: February 2013

February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.

Update on Drugs and Drug News: January 2013

Update on Tofacitinib citrate tablets (Xeljanz®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®), Tocilizumab (Actemra®), C1 esterase inhibitor (human) (Cinryze®), and Doxycycline monohydrate 40 mg capsules (Apprilon®)

Update on Drugs and Drug News: November-December 2012

Update on drugs, approval dates, and comments. Poly-ureaurethane 16% nail solution (Nuvail™), Calcipotriene 0.005% foam (Sorilux™), Hyaluronic acid injectable gel (Restylane-L®) are covered.

Update on Drugs and Drug News: October 2012

Update on drugs, approval dates, and comments. Delayed-release prednisone tablets (Rayos®), Imiquimod 3.75% cream (Zyclara®), Lidocaine topical 5% patch, Clobetasol propionate 0.05% shampoo are covered.

Update on Drugs and Drug News: September 2012

Update on Emtricitabine + tenofovir disoproxil fumarate (Truvada®), Collagenase clostridium histolyticum (XIAFLEX®) and devices such as Computer-assisted system for hair follicle harvesting (ARTAS™ System), OTC HIV test (OraQuick® In-Home HIV), and Herpes simplex virus test (IMDx HSV-1/2 for Abbott m2000).

Update on Drugs and Drug News: July 2012

Update on drugs, approval dates, and comments. CIP-Isotretinoin (Absorica™), Tazarotene 0.1% foam (Fabior™), Butoconazole nitrate 2% vaginal cream, Multisource radiofrequency aesthetic device (Glow by EndyMed™), Low-level laser for circumferential upper arm reduction (Zerona®) are covered.

Update on Drugs and Drug News: June 2012

Update on Taliglucerase alfa for injection (Elelyso™ Differin®) as well as devices like Nd:YAG surgical laser (Fotona® XP Laser), Q-switched laser for melasma (Spectra™), Diode hair removal laser (Advantage™), Low-level laser diode device for circumferential reduction (i-Lipo™), Multiwavelength diode laser (Evolve® HPD)

Update on Drugs and Drug News: May 2012

Update on drugs, approval dates, and comments. Belimumab Adapalene (0.3% gel Differin®), Vemurafenib tablet (Zelboraf®), Wound care spray (Granulox®), as well as devices like the laser device for onychomycosis Harmony® XL are covered.

Update on Drugs and Drug News: April 2012

Update on drugs, approval dates, and comments. Ivermectin 0.5% lotion (Sklice™), Ipilimumab (Yervoy™), Vemurafenib (Zelboraf®), are covered, as well as the Cellulite removal laser device Cellulaze™ Cellulite Laser Workstation.

Update on Drugs and Drug News: March 2012

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

Update on Drugs and Drug News: February 2012

Update on drugs, approval dates, and comments. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Hyaluronic acid-based dermal filler (Belotero® Balance), Drospirenone 3 mg + ethinyl estradiol 0.02 mg (Vestura™) are covered.

Update on Drugs and Drug News: January 2012

Update on drugs, approval dates, and comments. Dimethicone 50% topical solution (Nyda®), Radiofrequency aesthetic device (EXILIS Focused RF™), Skin barrier protectant (Neosalus® Lotion) are covered.

Update on Drugs and Drug News: November-December 2011

Update on drugs, approval dates, and comments. Belimumab (Benlysta™), Tolnaftate 1% Cream (Tolnaftate-D™), Hydrocortisone 1% Cream (Hydrocortisone-D™), Ketoconazole 2% Foam are covered.

Update on Drugs and Drug News: October 2011

Update on drugs, approval dates, and comments. IncobotulinumtoxinA injection (Xeomin®), Vemurafenib tablets (Zelboraf™ cobas®), Icatibant injection (Firazyr®) are covered.

Update on Drugs and Drug News: September 2011

Update on Autologous cell therapy dermal filler [laVív® (azficel-T)], 5-fluorouracil cream 0.5% + Salicylic acid 10% (Actikerall®), Belimumab (Benlysta®), Ipilimumab (Yervoy™).

Update on Drugs and Drug News: July-August 2011

Update on drugs, approval dates, and comments. Human papillomavirus (HPV) test (Cobas® HPV Test Cobas® 4800 System), Betamethasone valerate 0.12% foam (Luxiq®) are covered.

Update on Drugs and Drug News: June 2011

Update on Peginterferon alfa-2b (Sylatron™), Imiquimod 3.75% cream (Zyclara®), experienced recurrence 12 weeks after therapy. (Adapalene 0.1% + benzoyl peroxide 2.5% gel Tactuo™), Collagenase clostridium histolyticum (Xiapex®), and updates on generic drugs.

Update on Drugs and Drug News: May 2011

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Ipilimumab (Yervoy™), Imiquimod 3.75% Cream (Vyloma™) are covered.

Update on Drugs and Drug News: April 2011

Update on drugs, approval dates, and comments. Gabapentin tablets GRALISE™(DM-1796), Oxychlorine compound (Epicyn™ HydroGel), Collagenase clostridium histolyticum (XIAPEX®) as well as drug news on HPV vaccines.

Update on Drugs and Drug News: March 2011

Update on drugs, approval dates, and comments. Spinosad 0.9% cream rinse (Natroba™), Light emitting diode (LED) skin rejuvenation system (Tanda™ Professional Rejuvenate), Voclosporin Voclera™ (ISA247) are covered.

Update on Drugs and Drug News: February 2011

Update on drugs, approval dates, and comments. Human papillomavirus quadrivalent (Types 6, 11, 16, and 18) recombinant vaccine (Gardasil®), Daptomycin for injection (Cubicin®) are covered.

Update on Drugs and Drug News: January 2011

Update on drugs, approval dates, and comments. Calcipotriene/Calcipotriol0.005% foam (Sorilux™), Ceftaroline fosamil (Teflaro™) are covered as well as an update on Health Canada on the use of tacrolimus (Protopic®) for atopic dermatitis.

Update on Drugs and Drug News: November 2010

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

Update on Drugs and Drug News: October 2010

October 2010: Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®), and recent news with Health Canada.

Update on Drugs and Drug News: September 2010

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

Update on Drugs and Drug News: July-August 2010

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Adapalene 0.1% gel, Antiseborrheic compound (K301/Kaprolac®) are covered.

Update on Drugs and Drug News: June 2010

Update on CD56-binding monoclonal antibody (huN901) + maytansinoid cytotoxic agent (DM1) IMGN901, Small molecule oxychlorine compound (Microcyn® Skin and Wound HydroGel), Antifungal agent (K101/Kaprolac®).

Update on Drugs and Drug News: May 2010

Update on drugs, approval dates, and comments. Imiquimod 3.75% cream (Zyclara™), Adapalene 0.1% lotion (Differin®), Polidocanol injection (Asclera®) are covered.

POPULAR